Supplier, contractor, CDMO, facility, and investigational medicinal product manufacturer audits, quality documentation and backlog support, and ISO/IEC 17025 laboratory assessments — so critical GMP work gets the experienced, independent judgment it needs, before someone else has to find the gaps for you. Led personally by Roberto L. Rivera, former Pfizer Senior Audit Manager II with four decades in cGMP and 24 years auditing.
Composite situations drawn from four decades in cGMP — not client testimonials.
"If I don't get this done and something slips through on an unaudited supplier, that's on me — nobody's going to remember the budget conversation."
— VP of Quality · meeting an annual supplier audit schedule
"If something goes wrong on their floor, it's still my product with my company's name on it — and I'm the one who has to explain it, to my boss, to the customer, maybe to the regulator."
— VP of Quality · product manufactured by a third-party CDMO
"I don't need someone to tell me we have gaps — I need to know which ones to fix first, before the inspectors walk in."
— Director of Quality · preparing for an upcoming inspection
"If an investigator walked in tomorrow and asked what's still open, I honestly don't know what we'd hand them. That's the part that keeps me up."
— Director of Quality · established manufacturer, understaffed QA group
"We've got contracts that require accreditation. If we don't pass, we don't keep them. And I can't tell from inside this lab whether we'd actually pass."
— Laboratory Director · pursuing ISO/IEC 17025 accreditation
"This is going into patients in a trial. If something's wrong at that manufacturer and I signed off on them, I don't know how I explain that to anybody."
— VP of Quality · clinical-stage biopharmaceutical company
Most of what lands on my desk falls into one of two categories.
Investigations, CAPAs, change controls, and validation documentation are aging, and a team already stretched by daily operations cannot safely absorb any more.
See Quality Documentation & Backlog Support →A supplier, CDMO, facility, laboratory, or investigational medicinal product manufacturer needs an objective assessment, and your internal team lacks the time or the distance to do it thoroughly.
See Audits & Assessments →
I audit your suppliers, contractors, laboratories, and facilities before the regulators do — and I find what a team that cannot safely absorb the work is bound to miss. Every audit closes with a prioritized findings report and a remediation roadmap your team can actually execute.
Implement that roadmap fully — and if a regulator issues a Warning Letter or similar notice on a deficiency I identified within the scope of my audit or assessment, after a fully documented remediation implementation, I refund your engagement fee.
Subject to the terms of the engagement letter.
You have already tried the alternatives. Here is what that experience looks like — and what working with me looks like instead.
Every situation above ends the same way: someone has to hand you something concrete. Here is exactly what that is. Every engagement is scoped to your situation — no generic packages, no long-term commitment — and I am the person doing the work, from day one to final report.
Senior-level work on your backlog of complaint investigations, laboratory investigations, manufacturing investigations, CAPAs, change controls, and validation reports — worked to approval. Batch records worked to release. This includes backlog generated by a 483 or Warning Letter response: your team owns the response and the commitments to the agency, and I add senior capacity to work the documentation. Your team is already consumed by daily operations and the backlog keeps piling up. A growing backlog rarely announces itself — it keeps building quietly until someone outside your team asks to see it, and by then, catching up isn't a staffing problem anymore, it's a finding.
A customized audit plan and a written audit report, issued within 30 calendar days. Findings and an audit rating — Acceptable, Conditionally Acceptable, or Unacceptable. Prior CAPA implementation is checked as part of your next scheduled audit cycle. 90 days of consultation on the findings; qualification decisions and remediation effectiveness remain with your own QMS.
The same audit and reporting scheme applied to a CDMO's own manufacturing facility — drug products, biologics, and cell and gene therapy — typically 2–3 days, extending for multi-site operations involved in the audited product. Scope covers the CDMO's facility and their program for qualifying their own suppliers, not a physical audit of those third parties.
The same audit plan, report, and rating scheme applied to your own manufacturing facility and quality systems — an experienced, independent set of eyes with no loyalty to anyone on-site, mapped to FDA 21 CFR 210/211, 820, EMA, Health Canada, and regional standards, with findings that distinguish an isolated issue from a systemic risk, so you know not just what's wrong, but how urgently it needs to be fixed.
Clause-by-clause laboratory assessment by an ACLASS ISO 17025 Lead Assessor. Findings cited using standard nonconformity classification — major nonconformity, minor nonconformity, observation — with an overall rating of Conformity, Non-conformity (Conditional), or Non-conformity (Critical).
The same audit, report, and rating scheme applied to suppliers, investigational medicinal product (IMP) manufacturers, and laboratories supporting Phase I, II, and III supply chains — audit depth and rigor calibrated to the clinical phase and the maturity of the process being reviewed.
Each page covers what is included, how the engagement runs, and the questions clients ask most.
GMP Auditing & Consulting LLC was founded on a singular mission: to support the development and manufacture of safe and effective medical products for the treatment and prevention of human and animal diseases.
When critical GMP work carries regulatory, business, product, patient, and personal consequences, the difference between managing that risk and being managed by it is experience and independence — brought to bear before a gap becomes someone else's discovery.
Roberto spent 24 years at Pfizer and Wyeth as Senior Audit Manager II, leading all types of GMP audits within the Manufacturing and Supplier Quality Assessments Group across biotech, pharmaceutical, nutritional, medical device, consumer healthcare, and veterinary product suppliers on five continents. That work included auditing suppliers, contract manufacturers, and manufacturing facilities supporting a global vaccine supply chain built at unprecedented speed — and leading a portion of the compliance remediation at a manufacturing site operating under a Warning Letter.
Before that, he served as Director of Operations at Allergenics Inc., where he developed a novel oral vaccine formulation that produced an enhanced immune response — tested at the National Institutes of Health, with patents issued to the company.
His experience spans every major regulated product category and every major pharmaceutical regulatory body. He has personally performed Initial, Routine, Directed, and Pre-Approval audits of suppliers, contractors, laboratories, and manufacturing facilities, and holds an ACLASS ISO/IEC 17025 Lead Assessor credential for laboratory competence assessment.
In December 2021, Pfizer presented Roberto with a Compliance Division Rewards & Recognition Award — signed by Pfizer's Chief Compliance, Quality & Risk Officer at the time — in recognition of exceptional work on "Delivering COVID Vaccine Audits & Inspections with Excellence."
The number that matters most: zero closed CAPAs cited in Warning Letters. Every corrective and preventive action arising from his audits has held up under subsequent regulatory inspection — never reopened, never cited. That is the track record behind the Zero Warning Letter Guarantee.
Roberto holds a B.S. in Biology (Magna Cum Laude) and an MBA in General Management (Magna Cum Laude), and seven ASQ certifications including the rare CMQOE. Bilingual in English and Spanish, available across the Americas, Europe, India, China, Australia, and New Zealand.

Twenty-four years of hands-on GMP auditing across every major pharmaceutical and biotechnology discipline — built on four decades in cGMP operations, quality, and manufacturing.
Four decades of progressive leadership including some of the most recognized global pharma and medical device manufacturers — the judgement no regulation text can replicate.
I partner with pharmaceutical, biologics, medical device, consumer healthcare, and contract development and manufacturing organizations to supplement their quality resources — clearing documentation backlogs, and auditing and qualifying suppliers, contractors, laboratories, and facilities.
Member of the Manufacturing and Supplier Quality Assessments Group. Led cGMP compliance assessments of domestic and international biotech, pharmaceutical, nutritional, medical device, consumer healthcare, and veterinary product suppliers across five global regions. Lead Auditor for Initial, Routine, Directed, PAI, and Facility audits — including audits of suppliers, contract manufacturers, and manufacturing facilities supporting a global vaccine supply chain established under extraordinary time pressure.
Member of Wyeth Global Compliance Auditing Group. Division representative to Consumer Healthcare Quality Councils. Led a portion of the compliance remediation for a manufacturing area operating under a Warning Letter. Developed audit plans, guides, conformance assessment checklists, and auditor training programs covering a global supplier network across US, Canada, Europe, Asia, and Latin America.
Translated a university research project into a functional GMP corporate manufacturing operation. Developed a novel oral vaccine formulation producing an enhanced immune response — tested at the National Institutes of Health, with patents issued to the company.
Coordinated enzyme technology transfer between Cincinnati, Latin America, Asia/Japan, and Europe R&D centers. Managed contract manufacturing QA operations in Puerto Rico and the Caribbean. Supported new product line introductions following the Noxell acquisition.
Full QA responsibility: product testing, process validations, vendor audits, statistical process control, specification approval, label control, and equipment qualifications for liquids, creams, and ointments manufacturing.
Oversaw chemistry, microbiology, pyrogen, particle testing, calibrations, and sterilizer qualification labs for large volume parenterals and medical devices. Microbiological troubleshooting of aseptic filling operations and critical plant systems.
Established the Biochemical Operations Fermentation Laboratory for Tobramycin antibiotic manufacturing plant start-up. Designed yield optimization experiments achieving a 30% increase in product yield. QA chemistry and technical services for enzyme-based diagnostic reagents.
Cross-sector audit experience means I don't just know your regulations — I understand how they interact with your operational reality.
Every fee below sits under Big Four market rate — and carries a money-back guarantee the Big Four will never offer. Travel and reasonable expenses are billed at cost outside the Philadelphia metro area.
A backlog is a finding waiting to happen, and a single unqualified supplier can cost a mid-cap manufacturer millions in rejected lots, supply interruption, and regulatory findings that become your findings. Senior help is a fraction of that exposure.
Every engagement runs against a signed engagement letter and a numbered invoice. Payment is by ACH bank transfer or wire — the two methods your treasury team already uses for vendor payments. Purchase orders, W-9, certificate of insurance, and Net 30 terms are all supported for enterprise vendor onboarding.
Fair questions deserve direct answers — here is how the cost and the outcome actually work.
Every fee on this site sits below Big Four market rate for work led personally by someone with 24 years of GMP auditing experience as a former Pfizer and Wyeth Senior Audit Manager II — not an associate a few years out of school. There is no partner markup, no team of juniors billed alongside a supervising partner, and no long-term retainer required to get started. A single supplier audit or a scoped backlog engagement is a defined, bounded cost you can compare directly against the cost of a rejected lot, a supply interruption, or a regulatory finding that becomes your finding. And it is the only offer in this market backed by a money-back guarantee tied to the outcome, not just the hours worked.
The honest answer is the track record: zero closed CAPAs from my audits have ever been cited in a subsequent Warning Letter. Every corrective action I have signed off on has held under later regulatory scrutiny. That track record was built over 24 years inside the Manufacturing and Supplier Quality Assessments Group at Pfizer and Wyeth — including a Pfizer Compliance Division Rewards & Recognition Award for my work on COVID vaccine audits and inspections, and a portion of the compliance remediation on a site operating under a Warning Letter.
That is also why the Zero Warning Letter Guarantee exists: if you fully implement the roadmap from an audit or assessment and a regulator still cites a deficiency within its scope, the engagement fee is refunded. Skin in the game, not just a promise. The engagement is also backed by a Miscellaneous Professional Liability policy and a Commercial Liability Umbrella, providing $1M/$2M in coverage.
Tell me what you're behind on. I have almost certainly seen it before.
"I just need someone who has actually been in the trenches for decades to look at this and tell me exactly what's there — before the FDA does."
If that sounds familiar, schedule a complimentary GMP Quality Risk & Capacity Assessment — a focused 30-minute conversation, not a sales call. We'll cover:
You'll leave with a clearer picture of your situation and what to do next — no obligation to engage further. Most engagements are scoped and scheduled within two weeks. I respond personally within one business day.
Ready when you are.
GMP Quality Risk & Capacity Assessment